Cellosaurus logo
expasy logo

Cellosaurus 306D326.26 (CVCL_B0UY)

[Text version]
Cell line name 306D326.26
Synonyms LT1002; Sphingomab
Accession CVCL_B0UY
Resource Identification Initiative To cite this cell line use: 306D326.26 (RRID:CVCL_B0UY)
Comments Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized sonepcizumab (LT1009; Asonex) therapeutic antibody candidate for treatment of patients with cancer or ocular diseases.
Monoclonal antibody isotype: IgG1, kappa.
Monoclonal antibody target: ChEBI; CHEBI_37550; Sphingosine 1-phosphate (S1P).
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Category Hybridoma
Publications

PubMed=19509417; DOI=10.1194/jlr.M900048-JLR200; PMCID=PMC2759830
O'Brien N., Jones S.T., Williams D.G., Cunningham H.B., Moreno K., Visentin B., Gentile A., Vekich J., Shestowsky W., Hiraiwa M., Matteo R., Cavalli A., Grotjahn D., Grant M., Hansen G., Campbell M.-A., Sabbadini R.A.
Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies.
J. Lipid Res. 50:2245-2257(2009)

Patent=US9163091
Sabbadini R.A., Garland W.A., Hansen G., Swaney J.S., Matteo R., Mills G.B., Wojciak J.M.
Compositions and methods for binding lysophosphatidic acid.
Patent number US9163091, 20-Oct-2015

Cross-references
Cell line collections (Providers) ATCC; SD-5362 - Discontinued
Encyclopedic resources Wikidata; Q108819537
Entry history
Entry creation23-Sep-2021
Last entry update19-Dec-2024
Version number6